Abstract 3173
Background
Medication reconciliation (MedRec) including complementary and alternative medicine is considered as an important way to increase the safety of medication use. However, there are few studies in literature showing the impact of an oncogeriatric approach integrating MedRec program in elderly cancer patients (ECP). The objective is to measure the impact of a pharmacogeriatric approach (PGA) on ECP before treatment by chemotherapy.
Methods
A monocentric prospective study was implemented to evaluate the overall survival (OS), rate of readmission hospital (RRH) at 1stand 3rdmonth and Early Discontinuation of active treatment (ED). These variables were analyzed according to number of reviewed drugs in MedRec and geriatric tools of Comprehensive Geriatric Assessment (CGA).
Results
144 patients were received in oncogeriatric consultations between 01/2017 and 10/2017 (mean age was 80.9 ± 5.5 years, 52.1 % were men, 48.6 % had metastatic tumors). Main cancers were lung (31.9 %), gastrointestinal (18.1 %), breast and gynecological (16.7 %). At 1st and 3rdmonth, death rates were 3 % and 12 %; RRH were 11.1 % and 16.3 %. Received treatment was analyzed and 62.5% received systemic treatment after oncogeriatric consultations. Concerning ED at 3rd month, 48 % had prematurely stopped it (because of cancer progression in 14.2 % and infections in 7 %) and 23.6 % reduced dose (because of chemotoxicity in 33 % and geriatric conclusions in 20 %). OS prognostic factors were malnutrition (p = 0.03) and metastatic status (p = 0.05), prognosis factors of early death at 1 month were lymphopenia (p = 0.005) and RRH (p = 0.04), and at 3 months: malnutrition (p = 0.01), ADL dependence (p = 0.03), and RRH (p = 0.01).
Conclusions
To our knowledge, this is the first study evaluating and describing the outcomes of PGA with MedRec and CGA in same time for the ECP. First month death rates and RRH are lower compared to literature in our study. RRH, ADL and nutritional disorder are OS prognostic factors. Full analyzes will be presented during the congress to show the real impact of PGA.
Clinical trial identification
Legal entity responsible for the study
Assistance Publique Hôpitaux de Marseille.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract